Scarica l'app Stockscreener
21.57
1.27%
0.27
Precedente Chiudi:
$21.30
Aprire:
$21.62
Volume 24 ore:
425.21K
Relative Volume:
1.36
Capitalizzazione di mercato:
$1.47B
Reddito:
$350.00K
Utile/perdita netta:
$-72.78M
Rapporto P/E:
-19.97
EPS:
-1.08
Flusso di cassa netto:
$-54.46M
1 W Prestazione:
+18.91%
1M Prestazione:
-6.26%
6M Prestazione:
+48.55%
1 anno Prestazione:
+26.96%
Intervallo 1D:
$20.91
$22.82
Intervallo di 1 settimana:
$17.70
$22.82
Portata 52W:
$12.56
$26.30
Pulse Biosciences Inc Stock (PLSE) Company Profile
Nome
Pulse Biosciences Inc
Settore
Industria
Telefono
510-906-4600
Indirizzo
3957 POINT EDEN WAY, HAYWARD, CA
Compare PLSE vs ISRG, BDX, ALC, MDLN, RMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PLSE
Pulse Biosciences Inc
|
21.57 | 1.47B | 350.00K | -72.78M | -54.46M | -1.08 |
|
ISRG
Intuitive Surgical Inc
|
472.16 | 167.68B | 10.06B | 2.88B | 2.49B | 7.876 |
|
BDX
Becton Dickinson Co
|
159.36 | 45.33B | 21.92B | 1.76B | 2.63B | 6.1223 |
|
ALC
Alcon Inc
|
77.32 | 37.69B | 10.40B | 980.00M | 1.61B | 1.9749 |
|
MDLN
Medline Inc
|
41.46 | 33.65B | 28.43B | 1.16B | 1.26B | 1.4457 |
|
RMD
Resmed Inc
|
230.84 | 33.63B | 5.40B | 1.49B | 1.78B | 10.12 |
Pulse Biosciences Inc Stock (PLSE) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-30 | Iniziato | Mizuho | Outperform |
| 2025-07-07 | Iniziato | Oppenheimer | Outperform |
| 2021-07-27 | Iniziato | Stephens | Overweight |
| 2021-03-11 | Iniziato | Maxim Group | Buy |
| 2021-01-26 | Reiterato | H.C. Wainwright | Buy |
| 2020-05-12 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2020-02-14 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2019-02-25 | Iniziato | H.C. Wainwright | Buy |
Mostra tutto
Pulse Biosciences Inc Borsa (PLSE) Ultime notizie
Is Pulse Biosciences (PLSE) Pricing Make Sense After Recent Volatility And DCF Estimate Gap - simplywall.st
Responsive Playbooks and the PLSE Inflection - Stock Traders Daily
Pulse Biosciences enrolls first patients in thyroid cancer study By Investing.com - Investing.com India
A Look At Pulse Biosciences (PLSE) Valuation After Recent Share Price Swings - simplywall.st
Pulse Biosciences enrolls first patients in thyroid cancer study - Investing.com South Africa
Pulse Biosciences Launches Thyroid Cancer Feasibility Study - TipRanks
Pulse Biosciences, Inc. Announces First Enrollments in Feasibilit - The National Law Review
Pulse Biosciences, Inc. Announces First Enrollments in Feasibility Study for the Treatment of Malignant Thyroid Tumors with nPulse™ Technology - The Joplin Globe
Pulse Biosciences (NASDAQ:PLSE) Trading 8% HigherWhat's Next? - MarketBeat
Breakout Move: Can Pulse Biosciences Inc continue delivering strong returnsMarket Volume Summary & AI Forecast for Swing Trade Picks - baoquankhu1.vn
Durable Thyroid Nodule Ablation Data Could Be A Game Changer For Pulse Biosciences (PLSE) - Sahm
Pulse Biosciences (PLSE) Reports Promising Long-Term Outcomes fo - GuruFocus
Pulse Biosciences Earnings Call: Data Strength Vs. Cash Burn - TipRanks
Pulse Biosciences Announces Long-Term Clinical Data for nPulse Vybrance Percutaneous Electrode System in Benign Thyroid Nodule Ablation 71314 - Minichart
Pulse Biosciences Announces Clinical Data From nPulse Vybrance System First-In-Human Clinical Durability Study of Benign Thyroid Nodule Ablation - Investing News Network
Pulse Biosciences Reports Durable Thyroid Nodule Ablation Results - TipRanks
Pulse Biosciences (PLSE) reports 74% benign thyroid nodule reduction in nsPFA study - Stock Titan
Pulse Biosciences Announces Clinical Data From nPulse™ Vybrance™ System First-In-Human Clinical Durability Study of Benign Thyroid Nodule Ablation - Business Wire
Why Pulse Biosciences Inc. stock could be next big winnerEarnings Recap Summary & Fast Entry and Exit Trade Plans - Naître et grandir
How strong is Pulse Biosciences Inc. (6L8) stock earnings growthDividend Hike & Low Volatility Stock Recommendations - Naître et grandir
Pulse Biosciences' nPulse Vybrance System to be Featured in Multiple Presentations at the North American Society for Interventional Thyroidology Meeting - Investing News Network
A Look At Pulse Biosciences (PLSE) Valuation After Recent Share Price Momentum - simplywall.st
Pulse Biosciences to Present at the Oppenheimer 36th Annual Healthcare MedTech & Services Conference - The Joplin Globe
Pulse Biosciences at TD Cowen Conference: NSPFA Technology Shines - Investing.com
FinancialContentPulse Biosciences’ nPulse™ Vybrance™ System to be Featured in Multiple Presentations at the North American Society for Interventional Thyroidology Meeting - FinancialContent
PLSE Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Pulse Biosciences (NASDAQ:PLSE) Stock Passes Above 50 Day Moving AverageShould You Sell? - MarketBeat
Pulse Biosciences Highlights nPulse Cardiac Ablation Progress - TipRanks
Pulse Biosciences posts updated investor deck highlighting nPulse cardiac catheter and strengthened EP focus - TradingView
Pulse Biosciences (NASDAQ: PLSE) releases updated March 2026 investor deck - Stock Titan
Pulse Biosciences, Inc (PLSE) Stock Analysis: Is A 59% Upside Within Reach? - DirectorsTalk Interviews
Market Wrap: Does Pulse Biosciences Inc have strong fundamentalsWeekly Earnings Recap & Weekly Top Stock Performers List - baoquankhu1.vn
Understanding the Setup: (PLSE) and Scalable Risk - Stock Traders Daily
Pulse Biosciences (PLSE) clarifies disclosure on CCO Kevin Danahy’s resignation - Stock Titan
Pulse Biosciences Executive Sells 60,000 Shares - TradingView
Is Pulse Biosciences (PLSE) Pricing Make Sense After Recent Volatility And Cash Flow Forecasts? - Yahoo Finance
Pulse Biosciences (PLSE) Is Down 12.6% After Wider Losses And New Funding PlansHas The Bull Case Changed? - simplywall.st
PLSE Should I Buy - Intellectia AI
Pulse Biosciences chief commercial officer resigns effective immediately - Investing.com Nigeria
Pulse Biosciences Announces Resignation of Chief Commercial Officer - TipRanks
Chief Commercial Officer exits Pulse Biosciences (PLSE) with no stated dispute - Stock Titan
US med-tech companies bullish about 2026 - bioworld.com
Is Pulse Biosciences (PLSE) Share Price Justified After Recent Volatility In Healthcare Sentiment - simplywall.st
Pulse Biosciences (PLSE) Price Target Increased by 27.66% to 30.60 - Nasdaq
Pulse Biosciences, Inc (PLSE) Stock Analysis: Exploring a 48.59% Potential Upside in the Healthcare Sector - DirectorsTalk Interviews
ETF Watch: Will Perfect Corp Equity Warrant face regulatory challenges2025 Stock Rankings & Advanced Swing Trade Entry Plans - baoquankhu1.vn
Pulse Biosciences CCO Danahy sells $118k in PLSE stock By Investing.com - Investing.com Canada
Kevin Patrick Danahy Sells 5,000 Shares of Pulse Biosciences (NASDAQ:PLSE) Stock - MarketBeat
Pulse Biosciences (PLSE) CCO exercises options and sells 5,000 shares - Stock Titan
Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)February 20, 2026 - BioSpace
Aug EndMonth: Is Pulse Biosciences Inc benefiting from innovation trendsTrade Entry Summary & Smart Swing Trading Techniques - baoquankhu1.vn
Pulse Biosciences Inc Azioni (PLSE) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Pulse Biosciences Inc Azioni (PLSE) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Danahy Kevin Patrick | Chief Commercial Officer |
Feb 18 '26 |
Sale |
23.64 |
5,000 |
118,200 |
43,298 |
| Danahy Kevin Patrick | Chief Commercial Officer |
Feb 12 '26 |
Option Exercise |
1.53 |
20,000 |
30,600 |
63,298 |
| Danahy Kevin Patrick | Chief Commercial Officer |
Feb 13 '26 |
Option Exercise |
1.53 |
20,000 |
30,600 |
63,298 |
| Danahy Kevin Patrick | Chief Commercial Officer |
Feb 17 '26 |
Option Exercise |
1.53 |
20,000 |
30,600 |
63,298 |
| Danahy Kevin Patrick | Chief Commercial Officer |
Feb 17 '26 |
Sale |
23.63 |
20,000 |
472,600 |
43,298 |
| Danahy Kevin Patrick | Chief Commercial Officer |
Feb 13 '26 |
Sale |
23.53 |
20,000 |
470,600 |
43,298 |
| Danahy Kevin Patrick | Chief Commercial Officer |
Feb 12 '26 |
Sale |
23.37 |
20,000 |
467,400 |
43,298 |
0.97%
1.61%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):